AUTIFONY THERAPEUTICS
Autifony Therapeutics Limited, a biotechnology company, develops medicines to treat hearing disorders such as hearing loss and tinnitus. The company was incorporated in 2011 and is based in London, United Kingdom.
AUTIFONY THERAPEUTICS
Industry:
Biotechnology Medical Device Therapeutics
Founded:
2011-01-01
Address:
London, England, United Kingdom
Country:
United Kingdom
Website Url:
http://www.autifony.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
39.67 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon Google Font API WordPress Pound Sterling GoDaddy SSL Fontello
Similar Organizations
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Current Advisors List
Current Employees Featured
Founder
Investors List
Innovate UK
Innovate UK investment in Venture Round - Autifony Therapeutics
Pfizer Venture Investments
Pfizer Venture Investments investment in Series A - Autifony Therapeutics
Imperial Innovations
Imperial Innovations investment in Series A - Autifony Therapeutics
SV Health Investors
SV Health Investors investment in Series A - Autifony Therapeutics
UCLB
UCLB investment in Series A - Autifony Therapeutics
International Biotechnology Trust
International Biotechnology Trust investment in Series A - Autifony Therapeutics
SV Health Investors
SV Health Investors investment in Seed Round - Autifony Therapeutics
Imperial Innovations
Imperial Innovations investment in Seed Round - Autifony Therapeutics
Official Site Inspections
http://www.autifony.com
- Host name: 172.67.151.6
- IP address: 172.67.151.6
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Autifony Therapeutics"
About Us – Autifony Therapeutics
Autifony is a leader in the translation of ion channel biology into promising new pharmaceutical approaches for the treatment of hearing disorders. View pipeline. Management and team. Our …See details»
Autifony Therapeutics - Crunchbase Company Profile …
Organization. Autifony Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Autifony Therapeutics may be growing as evidenced by a significant …See details»
Autifony Announces Exclusive Global License and Collaboration …
Stevenage, UK – 14 November 2023 – Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for rare CNS disorders and …See details»
Autifony Therapeutics - LinkedIn
Autifony Therapeutics | 2,488 followers on LinkedIn. Autifony are dedicated to developing new medicines to treat rare genetic CNS disorders | Autifony Therapeutics Limited (“Autifony”) is a ...See details»
Portfolio company Autifony signs global licencing deal worth up to ...
Nov 14, 2023 Autifony will lead drug discovery and preclinical development activities on the two targets. Subsequent to successful completion of such preclinical development, Jazz will lead …See details»
Autifony Therapeutics Company Profile 2024: …
Autifony Therapeutics General Information Description. Developer of drug discovery platform designed to treat disorders of the central nervous system. The company's platform helps to alleviate symptoms of schizophrenia, fragile X, …See details»
Autifony Therapeutics Ltd - Our spinouts - Portfolio - UCLB
Autifony Therapeutics is an independent UK-based biotechnology company formed in 2011 as a spinout from GSK, which retains equity in the company. The company is focused on the …See details»
Autifony Therapeutics | Stevenage Bioscience Catalyst
Autifony Therapeutics aims to develop new drugs to treat serious disorders of the central nervous system using pioneering science. Autifony Therapeutics Limited is a UK-based company …See details»
Investors – Autifony Therapeutics
Autifony Therapeutics Limited is a privately funded company. Main investors . Additional funding has been received from:See details»
AUTIFONY THERAPEUTICS LIMITED - Companies House
Filing history for AUTIFONY THERAPEUTICS LIMITED (07543962) People for AUTIFONY THERAPEUTICS LIMITED (07543962) Charges for AUTIFONY THERAPEUTICS LIMITED …See details»
Boehringer collaborates with Autifony on schizophrenia drug
3 days ago Boehringer will pay Autifony €25 million up front, with further payments of up to €17.5 million during the option period upon achievement of short-term milestones.See details»
Autifony Therapeutics - Contacts, Employees, Board Members
Organization. Autifony Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... About. Autifony Therapeutics has 2 current employee profiles, …See details»
Autifony Therapeutics - Funding, Financials, Valuation & Investors
Autifony Therapeutics is a biotechnology company developing medicines to treat hearing disorders such as hearing loss and tinnitus. Search Crunchbase. ... How much funding has …See details»
Management Team – Autifony Therapeutics
Founder and Chief Research Officer (Autifony Srl) Daniel Umbricht, M.D. Chief Medical Officer. Barbara Domayne-Hayman, DPhil. Chief Business Officer. Martin Gunthorpe, PhD. Chief …See details»
Autifony Announces Exclusive Global License and ... - BioSpace
Nov 14, 2023 STEVENAGE, England--(BUSINESS WIRE)-- Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for rare …See details»
Autifony Therapeutics - Craft
Autifony Therapeutics has 5 employees across 2 locations, $24.24 m in total funding, and £22.83 m in annual revenue in FY 2018. See insights on Autifony Therapeutics including office …See details»
Board of Directors – Autifony Therapeutics
About Us Board of Directors. John Berriman. Non-Executive Chairman. Charles H. Large, PhD. Chief Executive OfficerSee details»
Autifony Announces Exclusive Global License and Collaboration …
Nov 14, 2023 1de9.Q7atEQiYWenPgORawBThZ4hLq_UJc4Y51-FFyhKbYoE.D4D8em3TL6S8sI47i1u2MsUx86JzPe9a4YMEgirDL7ASj_JaTa4fr-LKgw Log inSee details»
News & Events – Autifony Therapeutics
2023. Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders 14 November 2023 …See details»